Core Viewpoint - WuXi Biologics (02269) expects a revenue growth of approximately 16.7% to RMB 21.79 billion for the fiscal year 2025, driven by successful execution of its "Follow and Win Molecules" strategy and advanced technology platforms [1] Group 1: Financial Projections - Gross margin is anticipated to increase by about 5 percentage points to 46% [1] - Adjusted gross profit is projected to grow by 25.5% to approximately RMB 10.638 billion [1] - Profit attributable to equity shareholders is expected to rise by approximately 45.3% to RMB 5.733 billion [1] - Adjusted net profit is forecasted to increase by about 22% to RMB 6.586 billion [1] Group 2: Growth Drivers - Revenue growth is attributed to the successful execution of the "Follow and Win Molecules" strategy, leading technology platforms, industry-best project delivery times, and a strong track record in project execution [1] - The integrated CRDMO platform is set to add 209 new comprehensive projects in 2025, bringing the total to a record high of 945 projects [1] - The expansion of services in the biopharmaceutical industry includes research discovery, pre-IND development, clinical, and commercial production, leveraging rapidly developing technologies such as bispecific antibodies and ADCs [1] Group 3: Additional Performance Factors - Performance growth is also driven by increased research service revenue from multiple advanced technologies [2] - Utilization of existing and new production capacities, including ramp-up at European production facilities [2] - Cost savings and efficiency improvements achieved through lean operational management systems and digital solutions, along with investment income from the portfolio [2]
药明生物盈喜：2025年股东应占利润同比增46.3%